Articles tagged with Glioblastomas
A critical new pathway to treating glioblastoma, a deadly brain tumor, may be found in the complex diversity of tumor tissue. CDI scientists identified lipids with potential therapeutic value, highlighting the importance of targeting signaling pathways in relation to cell function and resistance to therapy.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers at UCLA Jonsson Comprehensive Cancer Center and Semel Institute identified the gene P300 as a potential therapeutic target for treatment-resistant brain cancer glioblastoma multiforme. By blocking P300, tumor cells can be prevented from recovering and growing under the hostile conditions created by radiation therapy.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
UT Southwestern researchers have identified a molecular pathway responsible for glioblastoma's spread and found an existing drug that curbs tumor growth in animal models. A clinical trial is underway testing the effectiveness of tofacitinib in treating glioblastoma.
Researchers have developed an immunity-boosting postoperative treatment that could prevent glioblastoma relapse by targeting cancer stem cells with nanoparticles. The injectable gel promotes the cancer-killing immune response and reduces toxic side effects.
Researchers at University of Bristol developed mathematical models to assess biomarkers for detecting glioblastomas, a type of brain cancer. The study found that lowering the current biomarker threshold could lead to earlier detection using blood tests.
A novel T cell bispecific antibody targeting EGFRvIII mutant glioblastoma has demonstrated potent anti-tumor activity in preclinical models. The therapy harnesses the power of the immune system to selectively target and destroy cancer cells, offering a safer treatment option for patients.
Virginia Tech scientists have developed a novel 3D tissue-engineered model of the glioblastoma tumor microenvironment to learn why tumors return and what treatments will be most effective. The model accounts for cell types, fluid flow, and other aspects of the actual tumor environment, allowing for easy testing of drug therapies.
Researchers discover gene AVIL responsible for deadly brain tumor also causes two forms of childhood cancer, rhabdomyosarcoma. Blocking AVIL activity prevents formation of the disease in lab samples and mouse models.
Researchers have developed a biomimetic formulation to treat glioblastoma by harnessing lactate metabolism. The formulation, called M@HLPC, uses nanoparticles to deliver a combination of drugs that inhibit cancer cell growth and kill glioma cells.
Biomarkers have been identified that could be targeted by novel drugs to treat glioblastoma brain tumors, which are highly lethal. The researchers found that temozolomide-resistant glioblastoma relies on a protein called CLK2, and that inhibiting its activity can cause widespread cancer cell death.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Gliomas, a common brain and spinal cord tumor, undergo genetic evolution that alters their behavior at recurrence, leading to increased invasiveness and poorer prognosis. The study identified distinct phenotypes and cellular features associated with treatment resistance.
Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.
A team of MIT researchers has developed drug-carrying nanoparticles that can efficiently penetrate the brain and kill glioblastoma cells. Using a human tissue model, they showed that the particles could get into tumors and deliver chemotherapy drugs, including cisplatin, which effectively killed tumor cells.
Researchers have developed a novel therapeutic strategy for treating glioblastoma using allogenic stem cells that can target and kill tumor cells. The therapy demonstrated profound efficacy in preclinical models, with 100% of mice living over 90 days after treatment.
A receptor protein called insulin receptor is pivotal for brain stem cell longevity, according to a Rutgers study. The researchers also found that the same protein plays a crucial role in sustaining brain cancer cells.
A seven-year research project suggests that a short chain of amino acids, the HTL-001 peptide, is effective at targeting and inhibiting Hox genes responsible for GBM growth. The study offers hope for finding a solution to this devastating form of brain cancer.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Researchers discovered a novel mechanism for miR-10b activation in high-grade gliomas, implicating topologic reorganization of chromatin and long-non-coding RNAs. This finding suggests new RNA-targeted strategies for glioma therapy and points to the vulnerability of tumor-initiating cells.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A new study finds that Tumor Treating Fields (TTFields) activate the immune system and trigger an anti-tumor cell response, potentially effectively used together with immunotherapy approaches. TTFields' unique mechanism of action induces a downstream signaling pathway that initiates an active immune response against cancer cells.
Researchers at IBiS have developed a new treatment that completely eliminated glioblastoma tumors in animal models, offering a new therapeutic option against this aggressive disease. The therapy combines the use of ADI-PEG20 with focal brain radiotherapy and has shown promising results without side effects.
Four IIT researchers have been awarded €150,000 each from the European Research Council to develop groundbreaking technologies addressing health challenges, such as tumours, blindness, and amputations. Their projects aim to substitute critical raw materials in electronics and create multisensory systems for visually impaired infants.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A clinical trial has found selinexor to be effective in shrinking tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer. The treatment induced responses in certain patients and allowed some to stay on the medication for over 12 months.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers discovered that cyclotides from violets increase the power of TMZ in killing glioblastoma cancer cells by up to eight-fold. This breakthrough could lead to better treatment options for patients with this fatal form of brain cancer.
A new study shows that treating mice with glioblastoma with interleukin-7 in combination with radiation improves survival rates. The therapy increases T cell numbers and activity against cancer cells, offering promise for patients with low lymphocyte counts.
Researchers at VTC have developed a promising three-pronged approach to treating glioblastoma, a lethal brain cancer. By inhibiting two specific proteins with temozolomide, they created an effective 'triple combinational therapy' that overcame chemoresistance.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
A new nomogram tool helps predict patient-level survival probabilities, accounting for sex differences in glioblastoma. The study analyzed over 1,300 patients and recommends further research on biological mechanisms underlying these differences.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
A UCLA research team found that PD-1 blockade initially activates T cells and conventional dendritic cells in glioblastoma, but the immune microenvironment remains dominated by immunosuppressive cells. The study suggests that combining therapies targeting other checkpoint proteins and pathways may improve treatment outcomes.
Researchers at Northwestern University have discovered a new biomarker that can identify glioblastoma patients who are likely to respond to immunotherapy. The treatment has shown promise in prolonging the lives of patients with this malignant brain tumor, which currently has a poor prognosis.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
A study has identified a specific protein, PHF3, that plays an important role in transcription and modulates the reading process of DNA. The absence of PHF3 or its binding site SPOC may lead to neuronal production defects, which could be linked to autism and glioblastoma.
A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.
Researchers at Queen Mary University of London have discovered a new way to analyze diseased and healthy cells from the same patient, revealing potential targets for individualized treatments. The study's findings could also help predict patient response to current drugs, leading to improved survival rates.
A new study found that translocator protein 18 kDa (TSPO) correlates with worse survival outcomes in male glioblastoma patients compared to females. The variation in the protein's structure is associated with shorter overall and progression-free survival times, suggesting its potential as a prognostic biomarker.
A new antibody delivery technology enhances anti-PD-L1 antibody accumulation in glioblastoma by 33-fold, achieving a 60% complete response rate with long-term immune memory. The technology also suppresses immune-related adverse events.
Researchers developed a gel made of fibrin that improved the effectiveness of CAR-T cell immunotherapy for glioblastoma by enhancing T cell distribution and preventing tumor recurrence. In mouse studies, the gel showed promising results, with 64% of treated mice being tumor-free after 94 days.
Researchers at the University of Alabama at Birmingham discovered a small molecule that potently attenuates neuroinflammation in brain and glial cells. This finding presents a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury, and neuropathic pain.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers from NUS Yong Loo Lin School of Medicine have discovered that glioblastoma cells depend on biotin distribution to grow and invade. This finding suggests that targeting biotin-dependent metabolic enzymes and epigenetic pathways may be a viable approach for treating glioblastoma.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers have developed poly-ion complex (PIC) nanomicelles loaded with CPT1A inhibitors to deliver drugs into brain cells, reducing fatty acid oxidation and improving treatment for glioblastoma. The delivery system successfully increased cellular concentration of the cargo and biological activity.
The study confirms the upregulation of TERT in primary glioblastomas and the gradual expression of all GABP components during malignancy progression. The authors found a positive association between TERT and B1L mRNA expression, highlighting the importance of GABPA/B isoforms in mutated TERT promoter-dependent gliomas.